Novartis failed to demonstrate in its attempt to secure pan-EU marketing approval for Xiidra (lifitegrast) that the dry eye treatment worked sufficiently well in the indication the company was seeking, the European Medicines Agency has found. The data package that was used to support the EU application was the same as that which secured the product's approval in the US back in July 2016.
Novartis AG withdrew its marketing authorization application (MAA) for lifitegrast 50 mg/ml eye drops solution from the EMA review...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?